COVID-19 & Cardiovascular
With the coronavirus disease 2019 (COVID-19) pandemic entering its third year, the extrapulmonary impact of the disease has become increasingly evident. For the cardiovascular system, infection with the etiologic virus, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), can manifest acutely and persist into convalescence and possibly beyond.1 Clinical outcomes are worse in patients with COVID-19 with cardiovascular disease and risk factors (eg, hypertension, diabetes, and obesity). Acute cardiac injury, inferred from elevations in cTn (cardiac troponin) levels, is reported in 8% to 62% of patients hospitalized with COVID-19 and is associated with greater disease severity, including the need for mechanical ventilation, and death.2–6
Among hospitalized patients with COVID-19, evidence of acute cardiac compromise is common and includes acute heart failure (3%–33%),71–73 cardiogenic shock (9%–17%),74 myocardial ischemia or infarction (0.9%–11%),71 ventricular dysfunction (left ventricular [10%–41%], right ventricular [33%–47%], biventricular [3%–15%]),75–78 stress cardiomyopathy (2%–5.6%),75,77 arrhythmias (9%–17%),71,72,74,79 venous thromboembolism (23%–27%),73 and arterial thrombosis secondary to viral-mediated coagulopathy.80
Diabetes Testing Centers™ helps medical providers offer our proprietary Post-COVID protocol program to patients.